Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | WNT1 | P04628 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132109 | 0.79 | CD274 (0.51) | DRD2DRD3CD274HDAC2HDAC8 | |
| SCHEMBL14082498 | 0.77 | WNT1 (0.64) | DRD2DRD3CD274WNT1DYRK1A | |
| SCHEMBL14082536 | 0.74 | MKNK1 (0.60) | DRD2DRD3CD274WNT1DYRK1A | |
| SCHEMBL14082516 | 0.74 | CD274 (0.77) | CD274WNT1DYRK1A | |
| SCHEMBL31387147 | 0.73 | SMN1; SMN2 (0.63) | DRD3HDAC2HDAC8HDAC6NAMPT | |
| SCHEMBL2136572 | 0.73 | HDAC1 (0.57) | HDAC2WNT1DYRK1A | |
| SCHEMBL20163145 | 0.73 | HDAC2 (0.51) | HDAC2WNT1DYRK1A | |
| SCHEMBL6643148 | 0.73 | MKNK1 (0.55) | DRD2DRD3NAMPT | |
| SCHEMBL14082489 | 0.68 | ALDH1A1 (0.61) | HDAC2HDAC8HDAC6NAMPTDYRK1A | |
| SCHEMBL17886705 | 0.68 | SMN1; SMN2 (0.77) | DRD2DRD3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | DRD2 2863/4885DRD3 2747/4885CD274 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.